CME Information
Up to 3 AMA PRA Category 1 Credit(s)™
Release date: September 2008 Valid through: September 2009
Course Material: CME Monograph (PDF)
Receiving CME Credit
To receive online CME credit for this activity, read the full activity then click below to complete the post-test and evaluation. You will be able to print your CME certificate immediately following completion of the post-test and evaluation.
You will have 2 opportunities to answer the questions correctly. Then you will be shown answers to any questions answered incorrectly, to be sure you understand the material. You will be able to print your CME certificate immediately following completion of the test and evaluation.
Target Audience
This activity is intended for oncologists, urologists and other medical professionals who assess, treat and counsel patients with metastatic bone cancer.
Educational Objectives
Following completion of this activity, participants should be able to:
- Discuss principal mediators of bone metastasis and targets of intervention.
- Discuss rationale for using adjuvant bone targeted therapies in preventing metastasis and bone loss.
- Assess current clinical data (safety and efficacy) for adjuvant bone targeted agents in preventing metastasis and bone loss.
Educational Need
The skeleton is both the most common organ affected by metastatic cancer and the site that produces the greatest morbidity for patients. Recent advances in our understanding of bone biology and the pathways by which cancer metastasizes and spread to bone have contributed to the development of several important new drugs targeting these processes, and focused research on further understanding the biology and targets involved in metastasis and bone loss. Oncologists, surgeons and other medical professionals need to be able to assess important new data and recommendations related to preventing bone metastasis, predicting who is at risk for skeletal-related events, and recent advances in clinical research in bone-targeted therapies so that they can more effectively counsel and treat their patients.
Sponsorship and Accreditation
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. InforMEDical is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity.
Educational Grant Support
Supported by educational grants provided by: Novartis Pharmaceuticals, Amgen Inc. and Merck & Co, Inc. Credit Designation InforMEDical designates this continuing medical education activity for up to 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Financial Disclosure
The program faculty disclosed the following financial relationships: Robert E. Coleman: Speaker: Novartis, Amgen, Roche; Consultant: Novartis, Amgen; Expert testimony: Novartis. Theresa A. Guise: Leadership: ASBMR, IBMS, Paget Foundation, ASCI; Consultant: Amgen; Speakers’ Bureau: Amgen, Merck and Novartis; Research funding: Scios. Allan Lipton: Consultant: Amgen, Novartis; Speakers’ Bureau: Amgen, Novartis. G. David Roodman: Consultant: Amgen, Novartis, Merck and Millennium; Speakers’ Bureau: Novartis; Scientific Advisory Board: International Myeloma Foundation and Multiple Myeloma Research Foundation. InforMEDical staff who contributed to planning and editing content, and individuals who provided independent peer review, have no financial relationships to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents, devices or diagnostics tools that have not been approved for use by the US FDA. The opinions expressed in the activity are those of the authors, and do not reflect those of the industry supporters or CME sponsor. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, contradictions and warnings. Participants/readers should appraise the information presented critically and are encouraged to consult appropriate resources for any product, device or diagnostic tool mentioned in this activity.